RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SinoMab BioScience Stock

SinoMab BioScience Liabilities 2024

SinoMab BioScience Liabilities

552.2 M CNY

Ticker

3681.HK

ISIN

HK0000544194

In 2024, SinoMab BioScience's total liabilities amounted to 552.2 M CNY, a 10.71% difference from the 498.77 M CNY total liabilities in the previous year.

SinoMab BioScience Aktienanalyse

What does SinoMab BioScience do?

SinoMab BioScience Ltd is a Chinese biotechnology company specializing in the research, development, and commercial production of innovative biopharmaceutical products. The company was founded in 2001 and is based in Hong Kong. The company's business model focuses on the development of antibody-based therapies for the treatment of cancer and inflammatory diseases. SinoMab BioScience Ltd collaborates closely with leading biopharmaceutical companies, academic institutions, and research facilities worldwide to develop therapeutics that have the potential to improve patients' lives. The company operates in various sectors, including research and development, production, and distribution of biopharmaceutical products. SinoMab also has its own research and development department dedicated to the discovery and development of antibodies. The company aims to build a pipeline of innovative products that address a wide range of medical needs. Currently, SinoMab BioScience Ltd has a range of product candidates in clinical development targeting the treatment of cancer and inflammatory diseases. One of the key products is the antibody preparation SMM-114, used for the treatment of patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma and represents one of the most common cancers in adults. SMM-114 actively inhibits the proliferation of tumor cells by blocking the protein CXCR4, which is expressed on the surface of cancer cells. Another important product candidate of the company is SMAB022, a monoclonal antibody for the treatment of patients with cutaneous squamous cell carcinoma. This product binds to the Epidermal Growth Factor Receptor (EGFR) protein on the surface of cancer cells and inhibits their proliferation. SinoMab BioScience Ltd also has a manufacturing and distribution department for biopharmaceutical products. The company has a GMP-compliant production facility and offers services such as process development, production and purification procedures, stabilization, and formulation of biopharmaceuticals. In addition, SinoMab BioScience Ltd has developed its own in vitro diagnostic (IVD) test for the detection of human papillomavirus (HPV). This disease is one of the most common sexually transmitted infections and is a serious health problem. The HPV IVD is an innovative test system that enables rapid, accurate, and reliable identification of HPV infections. Research and development is highly valued by the company, and it has established its own R&D department consisting of experienced scientists and engineers. This department focuses on the discovery and development of novel biopharmaceutical products and collaborates closely with academic institutions and research facilities. Furthermore, SinoMab BioScience Ltd has formed partnerships with other leading biopharmaceutical companies to collaborate in exploring and harnessing the potential of antibodies for the treatment of diseases. In conclusion, SinoMab BioScience Ltd is an innovative biotechnology company specializing in the development of novel biopharmaceutical therapies for the treatment of cancer and inflammatory diseases. The company has a strong research and development expertise and has built a pipeline of product candidates with the potential to improve patients' lives. With its wide range of products and services in the manufacturing and distribution of biopharmaceuticals, SinoMab BioScience Ltd has established a strong position in the market. SinoMab BioScience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing SinoMab BioScience's Liabilities

SinoMab BioScience's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating SinoMab BioScience's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing SinoMab BioScience's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

SinoMab BioScience's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in SinoMab BioScience’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about SinoMab BioScience stock

What is the level of liabilities of SinoMab BioScience this year?

SinoMab BioScience has a debt balance of 552.2 M CNY this year.

What were the liabilities of SinoMab BioScience compared to the previous year?

The liabilities of SinoMab BioScience have increased by 10.71% increased compared to the previous year.

What are the consequences of high debt for investors of SinoMab BioScience?

High liabilities can pose a risk for investors of SinoMab BioScience, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in SinoMab BioScience?

Low liabilities mean that SinoMab BioScience has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of SinoMab BioScience affect the company?

An increase in liabilities of SinoMab BioScience can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of SinoMab BioScience affect the company?

A decrease in the liabilities of SinoMab BioScience can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of SinoMab BioScience?

Some factors that can influence the liabilities of SinoMab BioScience include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of SinoMab BioScience so important for investors?

The liabilities of SinoMab BioScience are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can SinoMab BioScience take to modify the liabilities?

To change its liabilities, SinoMab BioScience can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does SinoMab BioScience pay?

Over the past 12 months, SinoMab BioScience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SinoMab BioScience is expected to pay a dividend of 0 CNY.

What is the dividend yield of SinoMab BioScience?

The current dividend yield of SinoMab BioScience is .

When does SinoMab BioScience pay dividends?

SinoMab BioScience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SinoMab BioScience?

SinoMab BioScience paid dividends every year for the past 0 years.

What is the dividend of SinoMab BioScience?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SinoMab BioScience located?

SinoMab BioScience is assigned to the 'Health' sector.

Wann musste ich die Aktien von SinoMab BioScience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SinoMab BioScience from 9/9/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did SinoMab BioScience pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of SinoMab BioScience in the year 2023?

In the year 2023, SinoMab BioScience distributed 0 CNY as dividends.

In which currency does SinoMab BioScience pay out the dividend?

The dividends of SinoMab BioScience are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SinoMab BioScience

Our stock analysis for SinoMab BioScience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SinoMab BioScience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.